Boehringer Ingelheim’s investigational dual GLP-1/glucagon receptor agonist survodutide produced significantly greater weight reduction than placebo in a Phase 3 trial in adults with obesity without diabetes, with efficacy assessed through week 76. In the randomized, double-blind study (SYNCHRONIZE-1; NCT06066515), 725 participants were assigned to once-weekly survodutide doses of 3.6 mg or 6.0 mg or placebo, in addition to lifestyle counseling. Mean body-weight change at week 76 was -12.2% for 3.6 mg, -13.0% for 6.0 mg, and -5.4% for placebo. Adverse events were dominated by gastrointestinal symptoms, occurring in 80.9% and 89.7% of the two active-dose groups versus 47.9% with placebo; no deaths were reported. The most common GI effects were described as typically mild to moderate. The results extend a highly competitive obesity drug landscape in which companies increasingly differentiate on dosing convenience, long-duration weight loss profiles, and tolerability management.